JP6952695B2 - インフルエンザウイルス複製の阻害剤、その適用方法および使用 - Google Patents
インフルエンザウイルス複製の阻害剤、その適用方法および使用 Download PDFInfo
- Publication number
- JP6952695B2 JP6952695B2 JP2018529614A JP2018529614A JP6952695B2 JP 6952695 B2 JP6952695 B2 JP 6952695B2 JP 2018529614 A JP2018529614 A JP 2018529614A JP 2018529614 A JP2018529614 A JP 2018529614A JP 6952695 B2 JP6952695 B2 JP 6952695B2
- Authority
- JP
- Japan
- Prior art keywords
- membered
- mmol
- independently
- mixture
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC1(*)CCCC(C(NC(CCC2)CC2NC)=O)=CC*CCC1 Chemical compound CC1(*)CCCC(C(NC(CCC2)CC2NC)=O)=CC*CCC1 0.000 description 2
- LPCWKMYWISGVSK-UHFFFAOYSA-N C(C1)C2CCCC1C2 Chemical compound C(C1)C2CCCC1C2 LPCWKMYWISGVSK-UHFFFAOYSA-N 0.000 description 1
- JSMRMEYFZHIPJV-IZLXSQMJSA-N C1[C@H]2CC[C@H]1C2 Chemical compound C1[C@H]2CC[C@H]1C2 JSMRMEYFZHIPJV-IZLXSQMJSA-N 0.000 description 1
- QGXBAXVERMIPRL-CLONCEMUSA-N CC(C)[n](cc1)c2c1c(N[C@@H](C1CCC3CC1)[C@H]3C(O)=O)nc(-c1c[nH]c3c1ccc(F)n3)n2 Chemical compound CC(C)[n](cc1)c2c1c(N[C@@H](C1CCC3CC1)[C@H]3C(O)=O)nc(-c1c[nH]c3c1ccc(F)n3)n2 QGXBAXVERMIPRL-CLONCEMUSA-N 0.000 description 1
- MNEXQPHUAARRJY-UHFFFAOYSA-N CCCCCCCCC[n](cc1)c2c1c(NC(C1CCC3CC1)C3C(O)=O)nc(-c1c[nH]c(nc3)c1cc3F)n2 Chemical compound CCCCCCCCC[n](cc1)c2c1c(NC(C1CCC3CC1)C3C(O)=O)nc(-c1c[nH]c(nc3)c1cc3F)n2 MNEXQPHUAARRJY-UHFFFAOYSA-N 0.000 description 1
- RNIJSZGJNGTOTB-UHFFFAOYSA-N CNC1C(CC2)CC2C1 Chemical compound CNC1C(CC2)CC2C1 RNIJSZGJNGTOTB-UHFFFAOYSA-N 0.000 description 1
- KOVMBBLCRKNEQZ-UHFFFAOYSA-N CNC1C(CC2)CCC2C1 Chemical compound CNC1C(CC2)CCC2C1 KOVMBBLCRKNEQZ-UHFFFAOYSA-N 0.000 description 1
- SLVGSEGMVWVKLR-UHFFFAOYSA-N C[n](cc1)c2c1c(NC(C1CCC3CC1)C3C(O)=O)nc(-c1c[nH]c(nc3)c1cc3F)n2 Chemical compound C[n](cc1)c2c1c(NC(C1CCC3CC1)C3C(O)=O)nc(-c1c[nH]c(nc3)c1cc3F)n2 SLVGSEGMVWVKLR-UHFFFAOYSA-N 0.000 description 1
- JDCSUKVUVKSDKF-UHFFFAOYSA-N C[n]1ncc(-c2cc(NC(C3CCC4CC3)C4C(O)=O)nc(-c(c3c4)c[nH]c3ncc4F)n2)c1 Chemical compound C[n]1ncc(-c2cc(NC(C3CCC4CC3)C4C(O)=O)nc(-c(c3c4)c[nH]c3ncc4F)n2)c1 JDCSUKVUVKSDKF-UHFFFAOYSA-N 0.000 description 1
- RDYONFOTBLXDOS-UHFFFAOYSA-N Cc([nH]c1c2cccn1)c2-c1nc([n](C)cc2)c2c(NC(C2CCC3CC2)C3C(O)=O)n1 Chemical compound Cc([nH]c1c2cccn1)c2-c1nc([n](C)cc2)c2c(NC(C2CCC3CC2)C3C(O)=O)n1 RDYONFOTBLXDOS-UHFFFAOYSA-N 0.000 description 1
- WUFVNVVIUUKSOB-UHFFFAOYSA-N Nc1nc(C(NC(CCC2)CC2Nc2nc(-c3c[nH]c(nc4)c3cc4F)nc(-c3ccccc3)c2)=O)c[s]1 Chemical compound Nc1nc(C(NC(CCC2)CC2Nc2nc(-c3c[nH]c(nc4)c3cc4F)nc(-c3ccccc3)c2)=O)c[s]1 WUFVNVVIUUKSOB-UHFFFAOYSA-N 0.000 description 1
- DPSZKYRAWZPFHN-UHFFFAOYSA-N OC(C(C1CCC2CC1)C2Nc1nc(-c(c2c3)c[nH]c2ncc3F)nc2c1cccc2)=O Chemical compound OC(C(C1CCC2CC1)C2Nc1nc(-c(c2c3)c[nH]c2ncc3F)nc2c1cccc2)=O DPSZKYRAWZPFHN-UHFFFAOYSA-N 0.000 description 1
- RENNLVZJNXATPF-MIJIDIFASA-N [O-][N+](c1ccc(-c2cc(N[I](C3CCC4CC3)[C@H]4C(O)=O)nc(-c3c[nH]c(nc4)c3cc4F)n2)[o]1)=O Chemical compound [O-][N+](c1ccc(-c2cc(N[I](C3CCC4CC3)[C@H]4C(O)=O)nc(-c3c[nH]c(nc4)c3cc4F)n2)[o]1)=O RENNLVZJNXATPF-MIJIDIFASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510908329 | 2015-12-09 | ||
| CN201510908329.2 | 2015-12-09 | ||
| PCT/CN2016/109079 WO2017097234A1 (en) | 2015-12-09 | 2016-12-08 | Inhibitors of influenza virus replication, application methods and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536681A JP2018536681A (ja) | 2018-12-13 |
| JP2018536681A5 JP2018536681A5 (OSRAM) | 2019-11-21 |
| JP6952695B2 true JP6952695B2 (ja) | 2021-10-20 |
Family
ID=59012608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529614A Active JP6952695B2 (ja) | 2015-12-09 | 2016-12-08 | インフルエンザウイルス複製の阻害剤、その適用方法および使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10717732B2 (OSRAM) |
| EP (1) | EP3362451B1 (OSRAM) |
| JP (1) | JP6952695B2 (OSRAM) |
| KR (1) | KR102671350B1 (OSRAM) |
| CN (2) | CN109748915B (OSRAM) |
| AU (1) | AU2016368317B2 (OSRAM) |
| RU (1) | RU2737190C2 (OSRAM) |
| SG (1) | SG11201804225PA (OSRAM) |
| WO (1) | WO2017097234A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109748915B (zh) * | 2015-12-09 | 2021-03-26 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其使用方法和用途 |
| WO2017198122A1 (zh) * | 2016-05-19 | 2017-11-23 | 四川大学 | 抗流感小分子化合物及其制备方法和用途 |
| WO2018033082A1 (en) | 2016-08-16 | 2018-02-22 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| WO2018041091A1 (en) | 2016-08-30 | 2018-03-08 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| US11136319B2 (en) * | 2016-09-05 | 2021-10-05 | Guangdong Raynovent Biotech Co., Ltd. | Anti-influenza virus pyrimidine derivative |
| US10987354B2 (en) | 2016-12-15 | 2021-04-27 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| WO2018127096A1 (en) | 2017-01-05 | 2018-07-12 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| WO2018157830A1 (en) | 2017-03-02 | 2018-09-07 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| PH12019502376B1 (en) | 2017-04-24 | 2024-06-05 | Cocrystal Pharma Inc | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication |
| CN109384783A (zh) * | 2017-08-09 | 2019-02-26 | 银杏树药业(苏州)有限公司 | 新型杂环化合物及其作为抗流感病毒抑制剂的医药用途 |
| MX2020008375A (es) * | 2018-02-08 | 2020-09-25 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Compuestos de heteroarilo, composiciones farmaceuticas de los mismos y su uso terapeutico. |
| US11535613B2 (en) | 2018-03-05 | 2022-12-27 | Guangdong Raynovent Biotech Co., Ltd. | Crystal form and salt form of pyridoimidazole compound and preparation method therefor |
| CN110590768B (zh) * | 2018-06-13 | 2021-02-26 | 银杏树药业(苏州)有限公司 | 杂环化合物、其组合物及其作为抗流感病毒药物的应用 |
| US20220354816A1 (en) * | 2019-09-27 | 2022-11-10 | Sunshine Lake Pharma Co., Ltd. | Oseltamivir formulation |
| CN110967239B (zh) * | 2020-01-02 | 2022-05-10 | 国家地质实验测试中心 | 一种金属铬溶解氧化方法 |
| WO2022007966A1 (zh) * | 2020-07-10 | 2022-01-13 | 四川海思科制药有限公司 | Pb2抑制剂及其制备方法和用途 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| EP4509494A1 (en) * | 2022-04-29 | 2025-02-19 | Tsinghua University | Plpro protein inhibitor, and preparation method and application thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2332940B1 (en) * | 2004-03-30 | 2012-10-31 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
| KR101903354B1 (ko) | 2009-06-17 | 2018-10-04 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
| WO2012083121A1 (en) | 2010-12-16 | 2012-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| EP2651940A1 (en) * | 2010-12-16 | 2013-10-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| KR20130128435A (ko) * | 2010-12-16 | 2013-11-26 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
| JP2014520815A (ja) * | 2011-07-05 | 2014-08-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | アザインドールを作製するための方法および中間体 |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| WO2013184985A1 (en) | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| SG10201804024VA (en) | 2013-11-13 | 2018-07-30 | Vertex Pharma | Formulations of azaindole compounds |
| DK3068776T3 (da) * | 2013-11-13 | 2019-07-29 | Vertex Pharma | Inhibitorer af replikation af influenzavira |
| ES2684755T3 (es) | 2013-11-13 | 2018-10-04 | Vertex Pharmaceuticals Incorporated | Métodos para preparar inhibidores de la replicación de virus de la gripe |
| KR102488479B1 (ko) | 2014-08-08 | 2023-01-12 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 인플루엔자 바이러스 감염에 사용하기 위한 인돌 |
| CN106661036B (zh) | 2014-09-08 | 2022-03-15 | 爱尔兰詹森科学公司 | 用于在流感病毒感染中使用的吡咯并嘧啶 |
| CN109748915B (zh) * | 2015-12-09 | 2021-03-26 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其使用方法和用途 |
| WO2017133664A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Bicyclic pyridine and pyrimidine derivatives and their use in the treatment， amelioration or prevention of influenza |
-
2016
- 2016-12-08 CN CN201910228694.7A patent/CN109748915B/zh active Active
- 2016-12-08 US US15/780,231 patent/US10717732B2/en active Active
- 2016-12-08 RU RU2018124993A patent/RU2737190C2/ru active
- 2016-12-08 CN CN201611123253.3A patent/CN106854205B/zh active Active
- 2016-12-08 SG SG11201804225PA patent/SG11201804225PA/en unknown
- 2016-12-08 KR KR1020187019477A patent/KR102671350B1/ko active Active
- 2016-12-08 AU AU2016368317A patent/AU2016368317B2/en active Active
- 2016-12-08 WO PCT/CN2016/109079 patent/WO2017097234A1/en not_active Ceased
- 2016-12-08 JP JP2018529614A patent/JP6952695B2/ja active Active
- 2016-12-08 EP EP16872423.5A patent/EP3362451B1/en active Active
-
2020
- 2020-06-09 US US16/897,256 patent/US11225477B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200299294A1 (en) | 2020-09-24 |
| US20180346463A1 (en) | 2018-12-06 |
| EP3362451B1 (en) | 2023-04-12 |
| AU2016368317B2 (en) | 2019-05-23 |
| CN106854205A (zh) | 2017-06-16 |
| AU2016368317A1 (en) | 2018-06-07 |
| KR102671350B1 (ko) | 2024-05-30 |
| RU2018124993A (ru) | 2020-01-14 |
| CN109748915A (zh) | 2019-05-14 |
| EP3362451A1 (en) | 2018-08-22 |
| SG11201804225PA (en) | 2018-06-28 |
| JP2018536681A (ja) | 2018-12-13 |
| RU2018124993A3 (OSRAM) | 2020-02-05 |
| CN109748915B (zh) | 2021-03-26 |
| CN106854205B (zh) | 2019-07-09 |
| WO2017097234A1 (en) | 2017-06-15 |
| US10717732B2 (en) | 2020-07-21 |
| RU2737190C2 (ru) | 2020-11-25 |
| CA3005921A1 (en) | 2017-06-15 |
| KR20180088466A (ko) | 2018-08-03 |
| US11225477B2 (en) | 2022-01-18 |
| EP3362451A4 (en) | 2019-07-03 |
| HK1254668A1 (en) | 2019-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6952695B2 (ja) | インフルエンザウイルス複製の阻害剤、その適用方法および使用 | |
| US10647693B2 (en) | Inhibitors of influenza virus replication, application methods and uses thereof | |
| JP7034162B2 (ja) | インフルエンザウイルス複製の阻害剤及びその使用 | |
| US10501444B2 (en) | Inhibitors of influenza virus replication, application methods and uses thereof | |
| US11098042B2 (en) | Inhibitors of influenza virus replication and uses thereof | |
| US10927118B2 (en) | Inhibitors of influenza virus replication and uses thereof | |
| CN108727369A (zh) | 流感病毒复制抑制剂及其用途 | |
| CN110117285B (zh) | 流感病毒复制抑制剂及其用途 | |
| CA3005921C (en) | Substituted-(pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin derivatives and use thereof as inhibitors of influenza virus replication | |
| HK1254668B (en) | Inhibitors of influenza virus replication, application methods and uses thereof | |
| HK40011744B (en) | Inhibitors of influenza virus replication and uses thereof | |
| HK40011744A (en) | Inhibitors of influenza virus replication and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191011 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191011 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20191107 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200917 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200928 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20201106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201224 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210419 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210719 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210921 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210928 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6952695 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |